JERUSALEM, Dec. 27,
2023 /PRNewswire/ -- Scinai Immunotherapeutics
Ltd. (NASDAQ: SCNI), a biopharmaceutical company focused both
on development of inflammation and immunology (I&I)
biological products and provision of boutique CDMO services,
announced today that the Company will host an analyst and
investors webinar event on January 9,
2024.
CEO Amir Reichman will
review Scinai's 2023 accomplishments and discuss 2024 plans,
including the intention to bring Scinai's anti-IL-17 VHH antibody
('NanoAb') innovative psoriasis treatment into clinical trials by
the end of this year.
Webinar Details and Registration:
- Tuesday, January 9th
at 10am (ET)
- Space is limited. Register now at
https://us02web.zoom.us/webinar/register/6017030839657/WN_7HRajnRKQPCjEw0tBR-FPA
Time permitting, the webinar will be open to questions and
answers.
About Scinai Immunotherapeutics:
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) is a
biopharmaceutical company with two complementary business units,
one focused on in-house development of inflammation and immunology
(I&I) biological products beginning with an innovative,
de-risked, pipeline of nanosized VHH antibodies (NanoAbs) targeting
diseases with large unmet medical needs, and the other a boutique
CDMO providing services to help biotech companies efficiently bring
their products to market by leveraging Scinai's drug development
and GMP and non-GMP manufacturing capabilities for pre-clinical and
clinical studies. Company website: www.scinai.com.
Company Contact
Joshua
Phillipson | +972 8 930 2529 |
joshua.phillipson@scinai.com
Forward-Looking Statements
This press release
contains forward-looking statements within the meaning of the
Private Litigation Reform Act of 1995. Words such as "expect,"
"believe," "intend," "plan," "continue," "may," "will,"
"anticipate," and similar expressions are intended to identify
forward-looking statements. All statements, other than statements
of historical facts, included in this press release regarding
strategy, future operations, future financial position, future
revenue, projected expenses, prospects, plans and objectives of
management are forward-looking statements. Examples of such
statements include, but are not limited to, the timing of
NanoAb proof-of-concept studies and clinical trials. These
forward–looking statements reflect management's current views with
respect to certain current and future events and are subject to
various risks, uncertainties and assumptions that could cause the
results to differ materially from those expected by the management
of Scinai Immunotherapeutics Ltd. Risks and
uncertainties include, but are not limited to, the risk that the
Company's financial health will not be positively impacted by the
amendment of the finance contract; the risk that the Company will
not remain listed on Nasdaq; the risk that the Company will not be
successful in becoming an end-to-end provider of CDMO
services at high international standards; the risk that
Scinai may not be able to secure additional capital on attractive
terms, if at all; the risk that the therapeutic and commercial
potential of NanoAbs will not be met; the risk of a delay in the
preclinical and clinical trials data for NanoAbs, if any; the risk
that our business strategy may not be successful; the risk that the
European Investment Bank (EIB) may accelerate the financial
facility under its finance contract with Scinai; Scinai's ability
to acquire rights to additional product opportunities; Scinai's
ability to enter into collaborations on terms acceptable to Scinai
or at all; timing of receipt of regulatory approval of Scinai's
manufacturing facility in Jerusalem, if at all or when required; the
risk that the manufacturing facility will not be able to be used
for a wide variety of applications and other vaccine and treatment
technologies; and the risk that drug development involves a lengthy
and expensive process with uncertain outcomes. More detailed
information about the risks and uncertainties affecting the Company
is contained under the heading "Risk Factors" in the Company's
Annual Report on Form 10-K filed with the Securities and Exchange
Commission ("SEC") on April 17, 2023,
and the Company's subsequent filings with the SEC. Scinai
undertakes no obligation to revise or update any forward-looking
statement for any reason.
Logo -
https://mma.prnewswire.com/media/2281627/4414902/Scinai_Logo
View original
content:https://www.prnewswire.com/news-releases/scinai-nasdaq-scni-to-host-analyst-and-investor-webinar-on-january-9-302022768.html
SOURCE Scinai Immunotherapeutics Ltd.